Ascendis Pharma A/S, a company focused on developing medical solutions to combat diseases, has announced updates to its share capital structure and warrant issuance. The share capital stands fully paid at DKK 58,231,484, with a series of authorizations for the Board of Directors to issue warrants and increase share capital, both with and without pre-emptive rights for current shareholders. These strategic financial tools aim to incentivize key stakeholders and facilitate capital raises to support the company's growth objectives.